[HTML][HTML] Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …
Safety, immunogenicity, and efficacy of the NVX-CoV2373 COVID-19 vaccine in adolescents: a randomized clinical trial
…, AL Greninger, N Patel, A McGarry… - JAMA network …, 2023 - jamanetwork.com
Importance Greater than 20% of cases and 0.4% of deaths from COVID-19 occur in children.
Following demonstration of the safety and efficacy of the adjuvanted, recombinant spike …
Following demonstration of the safety and efficacy of the adjuvanted, recombinant spike …
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine
…, K Smith, G Chau, S Galbiati, A McGarry… - Expert Review of …, 2023 - Taylor & Francis
Introduction The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and …
respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and …
[HTML][HTML] NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial
…, X Zhou, J Kinol, E Underwood, W Woo, A McGarry… - Vaccine, 2023 - Elsevier
PREVENT-19, the pivotal phase 3 trial of the Novavax adjuvanted, recombinant spike protein
COVID-19 vaccine (NVX-CoV2373), demonstrated that the vaccine was well tolerated and …
COVID-19 vaccine (NVX-CoV2373), demonstrated that the vaccine was well tolerated and …
Safety, immunogenicity and efficacy of NVX-CoV2373 in adolescents in PREVENT-19: a randomized, phase 3 trial
…, P Roychoudhury, AL Greninger, N Patel, A McGarry… - medRxiv, 2022 - medrxiv.org
BACKGROUND Over 20% of cases and 0.4% of deaths from Covid-19 occur in children.
Following demonstration of safety and efficacy of the adjuvanted, recombinant spike protein …
Following demonstration of safety and efficacy of the adjuvanted, recombinant spike protein …
[HTML][HTML] Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and Mexico
…, J Nelson, H Dunbar, S Cloney-Clark, A McGarry… - medRxiv, 2023 - ncbi.nlm.nih.gov
Background. NVX-CoV2373, an adjuvanted, recombinant SARS-CoV-2 spike (rS) protein
vaccine, consistently demonstrated protective efficacy against COVID-19 in clinical trials and …
vaccine, consistently demonstrated protective efficacy against COVID-19 in clinical trials and …
Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Supplementary Information file was supposed to contain the Statistical Analysis Plan; this
was not uploaded to ejp so was not included in the Supplementary Information file. Updated …
was not uploaded to ejp so was not included in the Supplementary Information file. Updated …
LB746. Safety and Immunogenicity of a Booster Dose of Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) in Adults from the PREVENT-19 Trial in the United …
…, N Patel, JS Plested, A McGarry… - Open Forum …, 2022 - academic.oup.com
Background Novavax COVID-19 Vaccine, Adjuvanted (5 µg recombinant spike protein/50
µg Matrix-M TM adjuvant; NVX-CoV2373) has received regulatory authorizations for use in …
µg Matrix-M TM adjuvant; NVX-CoV2373) has received regulatory authorizations for use in …
Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial (preprint)
…, P Roychoudhury, AL Greninger, N Patel, A McGarry… - 2022 - pesquisa.bvsalud.org
BACKGROUND Over 20% of cases and 0.4% of deaths from Covid-19 occur in children.
Following demonstration of safety and efficacy of the adjuvanted, recombinant spike protein …
Following demonstration of safety and efficacy of the adjuvanted, recombinant spike protein …
Immune Correlates Analysis of the PREVENT-19 COVID-19 Vaccine Efficacy Clinical Trial (preprint)
In the randomized, placebo-controlled PREVENT-19 phase 3 trial conducted in the US and
Mexico of the NVX-CoV2373 adjuvanted, recombinant spike protein nanoparticle vaccine, …
Mexico of the NVX-CoV2373 adjuvanted, recombinant spike protein nanoparticle vaccine, …